L40.9 L20.9 L12.0 L10.0 L13.8 M32.9 M33.1 M34.9 L95.9
Conditions
Interventions
Group 1: Prospective, non-interventional analysis of adult patients (= 18 years old) with first diagnosis or clinical suspicion of an inflammatory or autoimmune skin disease.
In recruited patients, u
Sponsors
Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical suspicion or first diagnosis of an inflammatory or autoimmune skin disease; written and signed informed consent for enrollment.
Exclusion criteria
Exclusion criteria: Lacking capacity to give consent to participate; known severe illness (malignoma, severe autoimmune disease); systemic immunosuppressive medication; simultaneous participation in another clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objectives of this study include: 1) Quantification of trace element status at patient recruitment, depending on disease severity. Parameters: biomarkers of trace element status (e.g., selenium, selenoprotein P, copper, zinc), clinical disease severity scores (e.g., PASI - Psoriasis Area and Severity Index, SCORAD - SCORing Atopic Dermatitis, DLQI - Dermatology Life Quality Index). 2) Correlation of the initial trace element status with the course of disease. Parameters: biomarkers of trace element status (see above), clinical response parameters (e.g., PASI 90 response). 3) Time course analysis of new-onset autoimmunity to selenoprotein P within the first six months after diagnosis of an inflammatory or autoimmune skin disease. Parameters: autoantibodies to selenoprotein P (longitudinal measurement). | — |
Secondary
| Measure | Time frame |
|---|---|
| None. | — |
Countries
Germany
Contacts
Public ContactTabaël Lee Turan
Charité - Universitätsmedizin Berlin
Outcome results
None listed